Microencapsulated feruloyl esterase producing lactobacilli ameliorate lipid profiles and glycaemia in high fat diet-induced obese mice

MÁRQUEZ, ANTONELA; RUSSO, MATIAS; ABEIJÓN-MUKDSI, CLAUDIA; SANTACRUZ, ARLETTE; LÓPEZ MALO, AURELIO; GAUFFIN-CANO, PAOLA; MEDINA, ROXANA

Beneficial Microbes

Wageningen Academic Publishers

Año: 2018

1876-2883

AbstractThe effect of oral administration of spray-dried microcapsules of feruloyl esterase (FE) producing Lactobacillusfermentum CRL1446 (Lf) and Lactobacillus johnsonii CRL1231 (Lj) on high fat diet-induced obese mice wasinvestigated to evaluate whether these strains could be used as a biotherapeutic for obesity. Swiss albino mice weredivided into a normal diet fed group receiving empty microcapsules (control), a high fat diet plus empty microcapsules(HFD group), HFD plus microcapsules with Lf (HFD-Lf group) and HDF plus microcapsules with Lj (HFD-Ljgroup). Microcapsules containing Lf or Lj at a dose of ~107 cells/day/mouse were given orally for 7 weeks. Bodyweight gain, adiposity index, plasma leptin, lipid profiles, glycemia, insulinenia, oral glucose tolerance, intestinalFE, glutathione peroxidase and glutathione reductase (GR) were determined. Administration of lactobacilli (HFDLfand HFD-Lj groups) improved metabolic parameters (triglyceride, total cholesterol, low-density lipoproteincholesterol levels) and cardiovascular risk indicators (37-46% decreased of atherogenic index), and reduced bodyweight gain (29-38%), adiposity index (42-62%), plasma leptin levels, liver weight and fat deposition in liver. IntestinalFE activities significantly increased in HFD-Lf (62%) and HFD-Lj group (48%), thus improving hepatic GR activity(42% increment) compared to HFD group. Moreover, L. johnsonii increased HDL-cholesterol and L. fermentumreduced blood glucose to levels similar to the control. These FE-producing lactobacilli have the potential to improvebiomarkers involved in obesity by increasing intestinal FE activity.